Shenzhen YHLO Biotech Co., Ltd. (YHLO) is a leading supplier of in-vitro diagnostic products in China, of which the main businessis research & development, production and sales of in-vitro diagnostic instruments and reagents mainly based on chemiluminescence immunoassay, as well as the distribution of medical devices not manufactured by YHLO.
Since its establishment in 2008, the company has independently developed in-vitro diagnostic products. After more than ten years of technical accumulation, the company's chemiluminescence immunoassay platform using magnetic particle labeled withacridinium ester is approaching perfection. At present, YHLO has established a complete product portfolio of high, medium and low-end instruments (including Total Laboratory Automation or TLA), and hasa complete and distinctive clinical diagnostic menu, a sound and stable product quality management system, and the top-levelcapability of R&D andcommercialization of in-vitro diagnostic products in China.
The company's core products have been widelyrecognized in the market, with a share of over 40% in top-level Chinese hospitals, forming an outstanding channel and brand advantage. The company has grown into one of the leading domestic chemiluminescence brands, with outstanding advantages in the diagnostic fields of autoimmune diseases, reproductive health, diabetes, infectious diseases and others. The compound growth rate of revenue of the company's own products exceeds 60% from 2018 to 2020.
| Full name | Shenzhen YHLO Biotech Co., Ltd. |
|---|---|
| Abbreviations | YHLO |
| Code | 688575 |
| Founded | 2008-09-17 |
| Listing | 2021-05-17 |
| Domicile | Shenzhen, Guangdong |
| Website | http://www.szyhlo.com |
| ir@szyhlo.com | |
| STAR Theme | Biomedicine |
| CSRC Sector | Manufacturing |
| Has weighted voting rights structure? | N/A |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Earnings Per Share | 0.58 | 0.30 | 0.11 |
| R&D expenditure as a % of operating revenue | 10.33% | 9.29% | 7.30% |
| Operating Revenue | 999.01 | 877.36 | 728.64 |
| Net Income | 207.96 | 106.08 | 38.03 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Operating Revenue | 999.01 | 877.36 | 728.64 |
| Operating Costs | 397.96 | 432.67 | 440.19 |
| Operating Income | 246.57 | 126.01 | 50.13 |
| Pretax Income | 241.50 | 125.98 | 496.87 |
| Income Tax | 33.54 | 19.90 | 11.65 |
| Net Income | 207.96 | 106.08 | 38.03 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Assets | |||
| Current Assets-Total | 793.88 | 630.28 | 450.67 |
| Non-current Assets-Total | 529.54 | 445.34 | 387.69 |
| Total Assets | 1,323.42 | 1,075.61 | 838.36 |
| Liabilities | |||
| Current Liabilities-Total | 520.55 | 379.13 | 356.18 |
| Non-current Liabilities-Total | 38.89 | 118.14 | 149.36 |
| Total Liabilities | 559.45 | 497.28 | 505.53 |
| Stockholder's Equity | |||
| Share Capital | 377.24 | 377.01 | 233.01 |
| Retained Profits | 390.55 | 202.39 | 99.82 |
| Minority Interests | -3.81 | -1.07 | - |
| Total Owners' Equity | 763.98 | 578.34 | 332.83 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Net Cash Flows-Operating | 282.16 | 68.34 | 29.71 |
| Net Cash Flows-Investing | -167.76 | -146.54 | -184.32 |
| Net Cash Flows-Financing | -8.76 | 142.44 | 133.55 |
| Name | No. of Shares Held (mn) | % of Shares Held |
|---|---|---|
| 胡鹍辉 | 158.69 | 39.18 |
| 深圳市普惠众联实业投资有限公司 | 33.18 | 8.19 |
| 何林 | 14.46 | 3.57 |
| 嘉兴睿耀股权投资合伙企业（有限合伙） | 12.50 | 3.09 |
| 深圳市华德赛投资咨询合伙企业（有限合伙） | 11.71 | 2.89 |
| 何石琼 | 11.20 | 2.77 |
| 彭少楷 | 9.63 | 2.38 |
| 深圳红土医疗健康产业股权投资基金合伙企业（有限合伙） | 9.63 | 2.38 |
| 苏州礼瑞股权投资中心（有限合伙） | 9.10 | 2.25 |
| 姚逸宇 | 7.63 | 1.88 |
All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.
Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.
Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.